Precision Biosciences annual operating margin
2018
2019
2020
2021
2022
2023
2024
2025
Precision Biosciences's operating margin was −152.19% for fiscal 2025.
View full Precision Biosciences company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −152.19% | −114.11 pp |
| 2024 | 2024-12-31 | −38.08% | +51.67 pp |
| 2023 | 2023-12-31 | −89.76% | +158.50 pp |
| 2022 | 2022-12-31 | −248.26% | −214.18 pp |
| 2021 | 2021-12-31 | −34.08% | +418.16 pp |
| 2020 | 2020-12-31 | −452.25% | −60.11 pp |
| 2019 | 2019-12-31 | −392.14% | +48.11 pp |
| 2018 | 2018-12-31 | −440.25% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −83.73% | +76164.54 pp |
| Q4 2025 | 2025-12-31 | 36.57% | +3930.93 pp |
| Q3 2025 | 2025-09-30 | −158,976.92% | −155283.35 pp |
| Q2 2025 | 2025-06-30 | −121,538.89% | −121587.28 pp |
| Q1 2025 | 2025-03-31 | −76,248.28% | −76224.46 pp |
| Q4 2024 | 2024-12-31 | −3,894.36% | −3682.79 pp |
| Q3 2024 | 2024-09-30 | −3,693.58% | −3599.35 pp |
| Q2 2024 | 2024-06-30 | 48.39% | +64.20 pp |
| Q1 2024 | 2024-03-31 | −23.81% | +128.28 pp |
| Q4 2023 | 2023-12-31 | −211.57% | −298.91 pp |
| Q3 2023 | 2023-09-30 | −94.23% | +105.09 pp |
| Q2 2023 | 2023-06-30 | −15.81% | +757.85 pp |
| Q1 2023 | 2023-03-31 | −152.10% | +671.99 pp |
| Q4 2022 | 2022-12-31 | 87.35% | +572.03 pp |
| Q3 2022 | 2022-09-30 | −199.32% | −151.30 pp |
| Q2 2022 | 2022-06-30 | −773.66% | −805.10 pp |
| Q1 2022 | 2022-03-31 | −824.09% | −709.45 pp |
| Q4 2021 | 2021-12-31 | −484.68% | −219.25 pp |
| Q3 2021 | 2021-09-30 | −48.02% | +305.69 pp |
| Q2 2021 | 2021-06-30 | 31.44% | +3074.85 pp |
| Q1 2021 | 2021-03-31 | −114.64% | +278.28 pp |
| Q4 2020 | 2020-12-31 | −265.43% | +69.76 pp |
| Q3 2020 | 2020-09-30 | −353.71% | +98.04 pp |
| Q2 2020 | 2020-06-30 | −3,043.41% | −2600.46 pp |
| Q1 2020 | 2020-03-31 | −392.91% | −36.01 pp |
| Q4 2019 | 2019-12-31 | −335.19% | −9.18 pp |
| Q3 2019 | 2019-09-30 | −451.76% | −40.62 pp |
| Q2 2019 | 2019-06-30 | −442.96% | +204.05 pp |
| Q1 2019 | 2019-03-31 | −356.90% | +247.48 pp |
| Q4 2018 | 2018-12-31 | −326.01% | — |
| Q3 2018 | 2018-09-30 | −411.14% | — |
| Q2 2018 | 2018-06-30 | −647.01% | — |
| Q1 2018 | 2018-03-31 | −604.38% | — |
Over the last five reported fiscal years, Precision Biosciences's operating margin increased from −452.25% to −152.19%, a change of +300.05 percentage points. The latest reported quarter, Q1 2026, shows −83.73%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Precision Biosciences filings at SEC.gov ↗